Changing HIV market
July 8, 2010
HALF of all antiretroviral sales in
2019 will be attributed to current
pipeline products, according to
market analyst Datamonitor.
The company also predicted that
the rising population, increase in
life expectancy and better testing
methods will push up demand for
antiretrovirals.
However sales of existing
products are still expected to shrink
by a compound annual growth rate
of -6%, due largely to patent
expiries and increasing reductions
in healthcare spend post-economic
downturn.
“A current abundance of
efficacious human
immunodeficiency virus treatment
options means that convenience is
becoming an increasingly important
factor in HIV therapy,” said Nele
Jensen, healthcare analyst at
Datamonitor.
“Consequently, the development
of pipeline cross-class fixed dose
combinations will be the key
strategy to ensuring market share
for HIV drug developers over the
next decade,” he added.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 10
